Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 07h05 HE
|
Virios Therapeutics
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on...
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
06 nov. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
12 oct. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
18 sept. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
12 sept. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
14 août 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 août 2023 07h05 HE
|
Virios Therapeutics
- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the...
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
09 août 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
03 août 2023 16h05 HE
|
Virios Therapeutics
ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
InvestmentPitch Media Video Discusses LOVE Pharma’s Plans to Continue Developing a Portfolio of Innovative Products such as Naltrexone Encompassing Transdermal Drug Delivery Applications for Addictions and Long-COVID
07 nov. 2022 06h00 HE
|
InvestmentPitch Media and Love Pharma Inc
VANCOUVER, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- LOVE Pharma (CSE:LUV) (FSE:G1Q0) continues with its plans to develop a portfolio of innovative products encompassing transdermal drug...